浩欧博股价跌5.09%，兴业基金旗下1只基金重仓，持有9.69万股浮亏损失96.89万元

Group 1 - The core point of the news is that Jiangsu Haobo Bio-Pharmaceutical Co., Ltd. experienced a decline in stock price, dropping by 5.09% to 186.50 CNY per share, with a total market capitalization of 11.839 billion CNY [1] - The company specializes in the research, production, and sales of in vitro diagnostic reagents, with its main revenue sources being reagent sales (89.46%), other sales (5.86%), instrument sales (3.84%), and rental sales (0.85%) [1] Group 2 - From the perspective of fund holdings, only one fund, Xingye Healthcare A (011466), has a significant position in Haobo, holding 96,900 shares, which accounts for 3.8% of the fund's net value [2] - Xingye Healthcare A has a current scale of 261 million CNY and has reported a year-to-date return of 19.68%, ranking 4159 out of 8100 in its category [2] - The fund manager, Chen Xu, has been in charge for 4 years and 287 days, with the fund's best and worst returns during his tenure being -23.28% and -25.09%, respectively [2]